Dyne Therapeutics Shares Jump 3.5% on Q2 Exon 51 Skipper Approval Plan
Dyne Therapeutics shares rose 3.54% as investors anticipated its Q2 plan to seek accelerated FDA approval for its Exon 51 skipper. This move could intensify competition with Sarepta’s Elevidys following a 33% year-over-year sales decline and planned CEO transition at its rival.
1. Stock Movement
Dyne Therapeutics shares climbed 3.54% during premarket trading, driven by investors’ optimism over its regulatory strategy and weakened competition.
2. Exon 51 Skipper Approval Plan
The company plans to submit its Exon 51 skipper application for accelerated FDA approval in the second quarter of 2026, targeting a faster pathway to market for Duchenne muscular dystrophy patients.
3. Competitive Context
If approved, the Exon 51 therapy could capture market share from Sarepta’s Elevidys, which reported a 33% year-over-year sales drop and is undergoing a CEO transition.
4. Investor Outlook
Investors view Dyne’s regulatory push and Sarepta’s leadership change as potential catalysts to boost Dyne’s top-line growth and market positioning in 2026.